JP2018528236A - 真皮障害を治療または予防するための新規組成物および方法 - Google Patents

真皮障害を治療または予防するための新規組成物および方法 Download PDF

Info

Publication number
JP2018528236A
JP2018528236A JP2018515561A JP2018515561A JP2018528236A JP 2018528236 A JP2018528236 A JP 2018528236A JP 2018515561 A JP2018515561 A JP 2018515561A JP 2018515561 A JP2018515561 A JP 2018515561A JP 2018528236 A JP2018528236 A JP 2018528236A
Authority
JP
Japan
Prior art keywords
rapamycin
cells
solvate
diastereomer
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018515561A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528236A5 (https=
Inventor
クリスチャン セル
クリスチャン セル
ティモシー ナカレッリ
ティモシー ナカレッリ
アシュレイ エイザー
アシュレイ エイザー
Original Assignee
ドレクセル ユニバーシティ
ドレクセル ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドレクセル ユニバーシティ, ドレクセル ユニバーシティ filed Critical ドレクセル ユニバーシティ
Publication of JP2018528236A publication Critical patent/JP2018528236A/ja
Publication of JP2018528236A5 publication Critical patent/JP2018528236A5/ja
Priority to JP2021169263A priority Critical patent/JP7332666B2/ja
Priority to JP2023130574A priority patent/JP7573078B2/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018515561A 2015-09-24 2016-09-19 真皮障害を治療または予防するための新規組成物および方法 Withdrawn JP2018528236A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021169263A JP7332666B2 (ja) 2015-09-24 2021-10-15 真皮障害を治療または予防するための新規組成物および方法
JP2023130574A JP7573078B2 (ja) 2015-09-24 2023-08-10 真皮障害を治療または予防するための新規組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562232228P 2015-09-24 2015-09-24
US62/232,228 2015-09-24
PCT/US2016/052442 WO2017053222A1 (en) 2015-09-24 2016-09-19 Novel compositions and methods for treating or preventing dermal disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021169263A Division JP7332666B2 (ja) 2015-09-24 2021-10-15 真皮障害を治療または予防するための新規組成物および方法

Publications (2)

Publication Number Publication Date
JP2018528236A true JP2018528236A (ja) 2018-09-27
JP2018528236A5 JP2018528236A5 (https=) 2019-10-31

Family

ID=58387119

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018515561A Withdrawn JP2018528236A (ja) 2015-09-24 2016-09-19 真皮障害を治療または予防するための新規組成物および方法
JP2021169263A Active JP7332666B2 (ja) 2015-09-24 2021-10-15 真皮障害を治療または予防するための新規組成物および方法
JP2023130574A Active JP7573078B2 (ja) 2015-09-24 2023-08-10 真皮障害を治療または予防するための新規組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021169263A Active JP7332666B2 (ja) 2015-09-24 2021-10-15 真皮障害を治療または予防するための新規組成物および方法
JP2023130574A Active JP7573078B2 (ja) 2015-09-24 2023-08-10 真皮障害を治療または予防するための新規組成物および方法

Country Status (9)

Country Link
US (3) US10695326B2 (https=)
EP (2) EP4729121A2 (https=)
JP (3) JP2018528236A (https=)
KR (1) KR20180081501A (https=)
CN (2) CN115645534A (https=)
AU (1) AU2016325446B2 (https=)
CA (1) CA3037469C (https=)
ES (1) ES3060762T3 (https=)
WO (1) WO2017053222A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019527711A (ja) * 2016-08-10 2019-10-03 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 局所ラパマイシン療法
WO2020091070A1 (ja) * 2018-11-02 2020-05-07 株式会社 資生堂 オルタナティブオートファジー誘導剤を含む紫外線起因性炎症抑制剤
JP2022009168A (ja) * 2015-09-24 2022-01-14 ドレクセル ユニバーシティ 真皮障害を治療または予防するための新規組成物および方法
JP2022512671A (ja) * 2018-10-11 2022-02-07 ドレクセル ユニバーシティ 皮膚症状を治療または予防する方法
JP2023550472A (ja) * 2020-11-24 2023-12-01 エーエフティー ファーマシューティカルズ リミテッド ラパマイシン組成物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
KR102132921B1 (ko) * 2018-12-13 2020-07-13 영남대학교 산학협력단 조타로리무스를 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
WO2009046436A1 (en) * 2007-10-04 2009-04-09 Memorial Sloan-Kettering Cancer Center Methods for inhibiting senescence of epithelial cells
JP2012523239A (ja) * 2009-04-10 2012-10-04 ウウシィ ハーグ ファーマスーティカルズ，インク． 新規抗老化剤及びそれらを同定する方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US20040180430A1 (en) * 1999-09-07 2004-09-16 West Michael D. Methods of restoring telomere length and extending cell lifespan using nuclear transfer
US7026374B2 (en) 2002-06-25 2006-04-11 Aruna Nathan Injectable microdispersions for medical applications
WO2005010010A1 (en) 2003-07-16 2005-02-03 Wyeth Cci-779 isomer c
US20050250805A1 (en) * 2004-05-06 2005-11-10 Glenmark Pharmaceuticals Limited Pharmaceutical ointment formulations
CA2601694A1 (en) 2005-03-14 2006-09-21 Macrochem Corporation Enhancement of macrolide penetration through human skin
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
MXPA06008797A (es) * 2006-08-03 2008-02-04 Fernando Ahumada Ayala Preparacion topica para el tratamiento de enfermedades inflamatorias de la piel que contiene sirolimus.
WO2008143928A1 (en) 2007-05-15 2008-11-27 Puretech Ventures Methods and compositions for treating skin conditions
EP2362866B1 (en) 2008-11-11 2015-07-08 Signum Biosciences, Inc. Isoprenyl compounds and methods thereof
AU2013204219B2 (en) 2009-04-10 2015-05-07 Haiyan Qi Novel anti-aging agents and methods to identify them
CA2822746A1 (en) 2009-12-21 2011-06-30 Sarah Bacus Compositions and methods for treatment of vitiligo
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
CA2825786A1 (en) 2011-01-31 2012-08-09 Osaka University Externally-used drug for treating skin disorder and method for producing same
US20130102572A1 (en) 2011-04-12 2013-04-25 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
CA2854926A1 (en) * 2011-11-08 2013-05-16 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
US20150202187A1 (en) 2012-06-26 2015-07-23 Sarah Bacus Compositions and methods for treatment of vitiligo
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CN105899232A (zh) * 2013-11-13 2016-08-24 诺华股份有限公司 用于增强免疫应答的mTOR抑制剂
US9980976B2 (en) * 2015-02-17 2018-05-29 Northwestern University Use of REDD1 inhibitors to dissociate therapeutic and adverse atrophogenic effects of glucocorticoid receptor agonists
KR20180081501A (ko) 2015-09-24 2018-07-16 드렉셀유니버시티 진피 장애를 치료하거나 예방하는 신규한 조성물 및 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
WO2009046436A1 (en) * 2007-10-04 2009-04-09 Memorial Sloan-Kettering Cancer Center Methods for inhibiting senescence of epithelial cells
JP2012523239A (ja) * 2009-04-10 2012-10-04 ウウシィ ハーグ ファーマスーティカルズ，インク． 新規抗老化剤及びそれらを同定する方法

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022009168A (ja) * 2015-09-24 2022-01-14 ドレクセル ユニバーシティ 真皮障害を治療または予防するための新規組成物および方法
JP7332666B2 (ja) 2015-09-24 2023-08-23 ドレクセル ユニバーシティ 真皮障害を治療または予防するための新規組成物および方法
JP2023154020A (ja) * 2015-09-24 2023-10-18 ドレクセル ユニバーシティ 真皮障害を治療または予防するための新規組成物および方法
JP7573078B2 (ja) 2015-09-24 2024-10-24 ドレクセル ユニバーシティ 真皮障害を治療または予防するための新規組成物および方法
JP2019527711A (ja) * 2016-08-10 2019-10-03 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 局所ラパマイシン療法
JP2022512671A (ja) * 2018-10-11 2022-02-07 ドレクセル ユニバーシティ 皮膚症状を治療または予防する方法
WO2020091070A1 (ja) * 2018-11-02 2020-05-07 株式会社 資生堂 オルタナティブオートファジー誘導剤を含む紫外線起因性炎症抑制剤
JPWO2020091070A1 (ja) * 2018-11-02 2021-09-30 株式会社 資生堂 オルタナティブオートファジー誘導剤を含む紫外線起因性炎症抑制剤
JP7516252B2 (ja) 2018-11-02 2024-07-16 株式会社 資生堂 オルタナティブオートファジー誘導剤を含む紫外線起因性炎症抑制剤
JP2023550472A (ja) * 2020-11-24 2023-12-01 エーエフティー ファーマシューティカルズ リミテッド ラパマイシン組成物

Also Published As

Publication number Publication date
EP3352755A4 (en) 2019-04-03
AU2016325446B2 (en) 2021-05-13
US20180280362A1 (en) 2018-10-04
JP2022009168A (ja) 2022-01-14
JP7332666B2 (ja) 2023-08-23
CA3037469A1 (en) 2017-03-30
JP7573078B2 (ja) 2024-10-24
US10695326B2 (en) 2020-06-30
ES3060762T3 (en) 2026-03-30
WO2017053222A1 (en) 2017-03-30
EP3352755A1 (en) 2018-08-01
CN108348508A (zh) 2018-07-31
US20220031673A1 (en) 2022-02-03
HK1258696A1 (en) 2019-11-15
US20200281903A1 (en) 2020-09-10
AU2016325446A1 (en) 2018-04-19
EP4729121A2 (en) 2026-04-22
KR20180081501A (ko) 2018-07-16
JP2023154020A (ja) 2023-10-18
CA3037469C (en) 2024-04-16
US11179374B2 (en) 2021-11-23
EP3352755B1 (en) 2025-12-24
CN115645534A (zh) 2023-01-31

Similar Documents

Publication Publication Date Title
JP7573078B2 (ja) 真皮障害を治療または予防するための新規組成物および方法
Nadal et al. Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: a systematic review
US9555034B2 (en) Compositions and methods for treating skin cancer associated diseases
US9358236B2 (en) Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
US10765682B2 (en) Apilimod for use in the treatment of melanoma
WO2015069217A1 (en) Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
US10799473B2 (en) Methods of inhibiting IGF-1R activation or downtream signalling thereof to reduce radiation-induced cellular senescence
KR20010033092A (ko) 발기부전 치료에 효과적인 조합물
US20170071903A1 (en) Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
TW201244716A (en) Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor
US12465605B2 (en) Methods and materials for gender-dependent treatment of cardiovascular dysfunction
HK1258696B (en) Topical composition comprising rapamycin for use in treating or preventing seborrheic keratosis or actinic keratosis
PT1682131E (pt) Cci-779 para o tratamento do linfoma de células do manto

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200923

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201221

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210322

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210322

AA91 Notification that invitation to amend document was cancelled

Free format text: JAPANESE INTERMEDIATE CODE: A971091

Effective date: 20210525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211015

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211015

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20211027

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20211119